173039-05-9

Basic information

• Product Name: Pentanedioic acid, 2-methylene-, bis(phenylmethyl) ester
• Synonyms: dibenzyl 2-Methylenepentanedioate;dibenzyl 2-methylenepentane-1,5-dioate;dibenzyl 2-methyleneglutarate;2-methylenepentanedioic acid dibenzyl ester
• CAS NO: 173039-05-9
• Molecular Formula: C20H20O4
• Molecular Weight: 324.376
• Mol File: 173039-05-9.mol

Chemical Properties

• Boiling Point: 424.1±30.0 °C(Predicted)
• Density: 1.142±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Pentanedioic acid, 2-methylene-, bis(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanedioic acid, 2-methylene-, bis(phenylmethyl) ester(173039-05-9)
• EPA Substance Registry System: Pentanedioic acid, 2-methylene-, bis(phenylmethyl) ester(173039-05-9)

Safety Data

• Hazardous Substances Data: 173039-05-9(Hazardous Substances Data)

Upstream product

• 2495-35-4 benzylacrylate 
• 56977-08-3 glutaric acid dibenzyl ester 

Downstream Products

• 263393-87-9 2-(2-nitro-ethyl)-pentanedioic acid dibenzyl ester 
• 263393-88-0 4,8-bis-benzyloxycarbonyl-6-nitro-undecanedioic acid dibenzyl ester 
• 263393-92-6 5-[Benzyloxy-(2,4-bis-benzyloxycarbonyl-butyl)-phosphinoyl]-4-benzyloxycarbonyl-pentanoic acid benzyl ester 
• 200698-34-6 2,4-di(benzyloxycarbonyl)butylphosphinic acid 
• 1027325-04-7 2-(benzyloxy-phenyl-phosphinoylmethyl)-pentanedioic acid dibenzyl ester 
• 1026633-17-9 2-(benzyloxy-propyl-phosphinoylmethyl)-pentanedioic acid dibenzyl ester 
• 1026553-58-1 2-[benzyloxy-(4-methoxy-benzyl)-phosphinoylmethyl]-pentanedioic acid dibenzyl ester 
• 1027914-51-7 2-[benzyloxy-(2-fluoro-benzyl)-phosphinoylmethyl]-pentanedioic acid dibenzyl ester 
• 1026377-34-3 2-[benzyloxy-(3,5-difluoro-benzyl)-phosphinoylmethyl]-pentanedioic acid dibenzyl ester 
• 848952-58-9 2-(benzyloxy-pentafluorophenylmethyl-phosphinoylmethyl)-pentanedioic acid dibenzyl ester 
• 897053-44-0 2-(diethylphosphonomethyl)-glutaric acid dibenzyl ester 
• 496812-78-3 (R)-2-(2-hydroxyphosphinoylmethyl)pentanedioic acid dibenzyl ester 
• 496812-79-4 (S)-(-)-2-(hydroxyphosphinoylmethyl)pentanedioic acid dibenzyl ester 

Relevant articles and documents

Diagnostic device for the detection of disease related target structures

The present invention provides a diagnostic device allowing highly specific and efficient in vivo and/or in vitro detection of a bio marker in a broad range of bodily fluids or tissues. The diagnostic device is composed of a binding agent that specificall

DIAGNOSTIC DEVICE FOR THE DETECTION OF DISEASE RELATED TARGET STRUCTURES

The present invention provides a diagnostic device allowing highly specific and efficient in vivo and/or in vitro detection of a bio marker in a broad range of bodily fluids or tissues. The diagnostic device is composed of a binding agent that specificall

DENDRIMER BASED COMPOSITIONS AND METHODS OF USING THE SAME

The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor).

DENDRIMER BASED COMPOSITIONS AND METHODS OF USING THE SAME

The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The c

Dendrimer based compositions and methods of using the same

The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The c

Prodrugs of NAALAdase inhibitors

The present invention relates to prodrugs of NAALADase inhibitors, pharmaceutical compositions comprising the same, and methods of using the same to treat glutamate abnormalities and prostate diseases.

NAALADase inhibitors useful as pharmaceutical compounds and compositions

The present invention relates to N-Acetylated α-Linked Acidic Dipeptidase (NAALADase) inhibitors enzyme activity, pharmaceutical compositions comprising such inhibitors, and methods of their use to inhibit NAALADase enzyme activity, thereby effecting neur

Design and pharmacological activity of phosphinic acid based NAALADase inhibitors

A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive model of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.

Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors

The present invention relates to methods of using NAALADase inhibitors for treating glutamate-mediated diseases, disorders and conditions selected from the group consisting of anxiety, anxiety disorders and memory impairment.

Methods of cancer treatment using naaladase inhibitors

The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated alpha -Linked Acidic Dipeptidase (NA